InvestLog
AKTX Akari Therapeutics, Plc logo

AKTX Akari Therapeutics, Plc

Healthcare
$18.27+255.45%ClosedMarket Cap: $20.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.03

P/S

0.00

EV/EBITDA

-0.65

DCF Value

$-13.95

FCF Yield

-52.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-123.3%

ROA

-82.8%

ROIC

-130.5%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-14.5M$—
Q4 null$0.00$-5.3M$—
FY null$0.00$-17.3M$—
Q3 null$0.00$-6.4M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$1,200.00

Target (Median)

$1,200.00

Target Range

$1,200.00 - $1,200.00

0 Strong Buy2 Buy1 Hold0 Sell0 Strong Sell
Maxim GroupHold
2026-04-08
HC Wainwright & Co.Buy
2026-04-01
HC Wainwright & Co.Buy
2025-09-09

Trading Activity

Insider Trades

View All
Neal James Rdirector
BuyMon Mar 16
Neal James Rdirector
BuyMon Mar 16
Prudo-Chlebosz Raymonddirector
BuyThu Dec 18
Prudo-Chlebosz Raymonddirector
BuyThu Dec 18
Patel Sandip Idirector
BuyThu Dec 18

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

GB

Exchange

—

Beta

0.65

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Peers

CDT logoCDTDRMA logoDRMAMSPR logoMSPRPBM logoPBMPPBT logoPPBTREVB logoREVBSYRS logoSYRSVINC logoVINCVRPX logoVRPXXAGE logoXAGE